Viatris Inc represents a set of core values and a corporate philosophy that guides its operations. The company is committed to delivering access to high-quality medicines worldwide, focusing on enhancing patient experiences and outcomes. Viatris aims to make a difference by providing reliable and affordable healthcare solutions, empowering people to live healthier lives. With a relentless dedication to innovation, integrity, and excellence, Viatris Inc fosters strong partnerships, embraces inclusivity, and prioritizes sustainability. By upholding these values, Viatris strives to positively impact global healthcare and create value for all stakeholders involved.

Viatris Inc is primarily present in multiple countries and regions around the world. Some of the key regions where the company has a significant presence include North America, Europe, and Asia-Pacific. This global pharmaceutical company operates in approximately 165 countries, providing a wide range of healthcare products and services. Viatris Inc's diverse geographic footprint allows it to cater to the needs of a diverse customer base and contribute to improving healthcare access and outcomes on a global scale.

Viatris Inc, a reputable pharmaceutical company, has achieved several significant milestones. These include the successful merger of Mylan and Upjohn to form Viatris in November 2020. This merger expanded Viatris' global reach and diversified its product portfolio, strengthening its position in the healthcare industry. Furthermore, Viatris has a robust pipeline of innovative generic and biosimilar products, allowing them to provide accessible and affordable healthcare solutions to patients around the world. With its strong commitment to excellence and continuous research and development, Viatris is poised to achieve even greater milestones in the future.

Viatris Inc. is a global pharmaceutical company formed through a merger between Mylan and Upjohn in November 2020. With a rich history, Viatris brings together the experience and expertise of these two renowned organizations. Mylan, founded in 1961, has a legacy of delivering high-quality, affordable medicine to people worldwide. Upjohn, established in 1886, has a long-standing commitment to improving health and well-being. As Viatris Inc., the company continues to build upon this strong foundation, striving to provide innovative treatments, enhance access to healthcare, and improve patient outcomes. With a global presence and a diversified product portfolio, Viatris remains dedicated to addressing unmet medical needs and improving lives.

The main competitors of Viatris Inc in the market include established pharmaceutical companies such as Pfizer, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Mylan NV, and Novartis AG.

Viatris Inc is primarily active in the pharmaceutical industry.

The business model of Viatris Inc is focused on the development, manufacturing, and distribution of generic and biosimilar pharmaceutical products. As a global healthcare company, Viatris aims to make high-quality medicines more accessible for patients worldwide. By leveraging their extensive research and development capabilities, manufacturing expertise, and strong distribution network, Viatris strives to deliver cost-effective healthcare solutions. With a diverse portfolio covering various therapeutic areas, Viatris is committed to enhancing patient lives by providing affordable and reliable pharmaceutical products across the globe.

مُعامل القيمة السوقية إلى الأرباح لـ Viatris هو ٤٫٣٧.

مُعامِل القيمة إلى المبيعات Viatris هو ٠٫٩٤.

نقاط جودة AlleAktien لـ Viatris هي 4/10.

المتوقعة Viatris الإيرادات هي ١٥٫١١ مليارات USD.

صافي الربح المتوقعة Viatris هو ٣٫٢٥ مليارات USD.

Viatris Inc is a globally operating pharmaceutical and healthcare company focused on the development, manufacturing, and distribution of high-quality generic drugs and biosimilars. The company is headquartered in Pennsylvania, USA and was formed through the merger of Pfizer's global generics division with Mylan in November 2020. Viatris serves patients in over 165 countries and is one of the largest providers of generic drugs and biosimilars worldwide.

يوزع Viatris أرباحًا قدرها ٠٫٤٨ USD من خلال 3 عمليات توزيع موزعة على مدار السنة.

Viatris يوزع أرباحًا 3 مرة في السنة.

الرمز الدولي للأوراق المالية الخاص بـViatris هو US92556V1061.

رمز WKN لـ Viatris هو A2QAME.

الرمز المُختصر لـ Viatris هو VTRS.

خلال آخر 12 شهراً، دفعت Viatris توزيعات أرباح بقيمة ٠٫٤٨ USD . وهذا يعادل عائد توزيعات أرباح يقارب ٤٫٠٨ %. ومن المتوقع أن تدفع Viatris خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ٠٫٥١ USD.

نسبة توزيعات الأرباح الحالية لـ Viatris هي ٤٫٠٨ %.

Viatris يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر ديسمبر, أبريل, يونيو, سبتمبر.

Viatris دفعت توزيعات الأرباح كل عام خلال الـ10 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة ٠٫٥١ USD. وهذا يعادل عائد توزيعات أرباح قدره ٤٫٣٧ %.

Viatris يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة ٠٫١٢ USD من Viatris المُعلن عنها في ١٣‏/٩‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٣‏/٨‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١٣‏/٩‏/٢٠٢٤.

في العام 2023، وزعت Viatris ٠٫٤٨ USD كأرباح أسهم.

يتم توزيع أرباح Viatris بالعملة USD.